List of Excipients in Branded Drug SONATA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	SONATA	zaleplon	54868-5139	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	SONATA	zaleplon	54868-5139	D&C YELLOW NO. 10
Physicians Total Care Inc	SONATA	zaleplon	54868-5139	FD&C BLUE NO. 1
Physicians Total Care Inc	SONATA	zaleplon	54868-5139	FD&C GREEN NO. 3
Physicians Total Care Inc	SONATA	zaleplon	54868-5139	FD&C YELLOW NO. 5
Physicians Total Care Inc	SONATA	zaleplon	54868-5139	GELATIN

SONATA (Zaleplon) Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

SONATA is the original brand for zaleplon, a short-acting nonbenzodiazepine hypnotic approved by the FDA for short-term treatment of insomnia. Its commercial exclusivity has expired, the brand has limited current market leverage, and generic zaleplon capsules dominate the opportunity. The strongest product-development paths are low-cost immediate-release capsules, orally disintegrating or liquid formulations, and differentiated products designed around rapid onset, dose flexibility, and controlled-substance handling.

What drug and dosage forms does SONATA contain?

SONATA contains zaleplon, a pyrazolopyrimidine hypnotic that acts at the benzodiazepine site of the GABA-A receptor complex. The drug has a short elimination half-life of approximately one hour, which supports use for sleep initiation when the patient has sufficient time remaining for sleep.[1]

Attribute	SONATA / zaleplon profile
Active ingredient	Zaleplon
FDA indication	Short-term treatment of insomnia
Original brand	SONATA
FDA NDA	020859
Common strengths	5 mg and 10 mg capsules
Dosage form	Immediate-release hard gelatin capsule
DEA status	Schedule IV controlled substance
Typical dose	10 mg for adults; 5 mg for older adults and selected patients
Pharmacokinetic profile	Rapid absorption; approximately one-hour half-life
Current market structure	Generic-dominated
Biosimilar relevance	None; zaleplon is a small molecule

The product is designed for rapid dissolution and absorption rather than extended exposure. That pharmacology limits the value of sustained-release strategies unless a developer targets a different clinical use, such as sleep maintenance.

What excipients are used in SONATA capsules?

The SONATA capsule uses a conventional solid oral excipient platform. The principal formulation objectives are powder flow, content uniformity at low drug load, capsule fill performance, rapid disintegration, and chemical stability.

Excipient or component	Likely formulation function
Lactose monohydrate	Diluent and capsule-fill bulking agent
Microcrystalline cellulose	Diluent, carrier, and flow-supporting excipient
Pregelatinized starch	Binder and disintegration aid
Silicon dioxide	Glidant and moisture-control support
Sodium lauryl sulfate	Wetting and dissolution aid
Magnesium stearate	Lubricant
Gelatin capsule shell	Dosage-form enclosure
Titanium dioxide and colorants	Capsule identification and appearance control

The exact excipient declaration should be confirmed against the applicable FDA labeling record and current generic product labels because manufacturers may use different inactive-ingredient systems.[2]

Why is the conventional excipient system commercially important?

Zaleplon is administered at a low dose, so the formulation has a relatively high excipient-to-active ratio. A robust filler and flow-control system is therefore important for:

• Uniform distribution of zaleplon through the blend.
• Accurate filling of 5 mg capsules.
• Consistent dissolution between strengths.
• Manufacturing on standard high-speed capsule equipment.
• Low-cost procurement from multiple excipient suppliers.
• Reduced regulatory complexity compared with novel delivery systems.

Lactose and microcrystalline cellulose provide a familiar commercial base. Pregelatinized starch supports compact powder processing without requiring a tablet compression step. Sodium lauryl sulfate can improve wetting of a poorly water-soluble active, although its level must be controlled because excessive surfactant can affect dissolution, gastrointestinal tolerability, and capsule-shell behavior.

What formulation patents protect SONATA and zaleplon?

The original SONATA franchise was protected primarily through composition-of-matter and product-related patent rights rather than a complex excipient platform. Those rights have expired, and generic zaleplon products have been approved for years.

Protection category	SONATA position	Commercial implication
Active pharmaceutical ingredient	Historical patent protection	Expired
Original capsule formulation	Historical product protection	No meaningful current barrier
Method of use	Insomnia treatment claims	Expired or commercially weak
Excipient combination	Conventional excipients	Limited exclusivity potential
Drug-device combination	Not central to original SONATA	Open opportunity if technically differentiated
Regulatory exclusivity	Historical NDA exclusivity	Expired
Generic approval pathway	ANDA	Available for conventional capsules

A new applicant would generally need a technically defensible formulation, manufacturing, or delivery innovation to create meaningful patent value. Repackaging the same inactive ingredients at different levels is unlikely to produce durable protection unless the change delivers an unexpected dissolution, stability, abuse-deterrence, bioavailability, or tolerability result.

When did SONATA lose exclusivity and when can generics launch?

SONATA’s commercial exclusivity is no longer a barrier to generic entry. FDA-approved generic zaleplon capsules have been available since the mid-2000s, and the conventional 5 mg and 10 mg products are subject to ordinary generic competition.[3]

Milestone	Status
Original FDA approval	1999
Branded regulatory exclusivity	Expired
Original patent estate	Expired
Generic capsule entry	Began in the mid-2000s
Current branded protection	No material market exclusivity
Current generic pathway	ANDA for equivalent immediate-release capsules

The practical launch question is no longer whether a generic can enter. It is whether a new entrant can secure adequate supply, obtain favorable reimbursement, and achieve sufficient volume to offset low generic pricing.

What is the Orange Book status of SONATA?

The Orange Book historically listed SONATA-related patent information associated with NDA 020859. Those listed rights do not provide a current commercial barrier to ordinary zaleplon capsule entry. A current applicant should still review the live Orange Book record before filing, especially if it seeks approval for a specific strength, formulation, or labeling strategy.[4]

For a conventional generic capsule, the likely regulatory route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence. If no unexpired Orange Book patent blocks approval, a Paragraph IV challenge is not the principal launch mechanism. A Paragraph III certification may apply to a listed patent with a later expiry, but the historical SONATA patent estate is not generally considered a live obstacle.

How strong is the current patent estate for zaleplon?

The current patent estate is weak for the original capsule product and stronger only where a developer creates a genuinely differentiated platform.

Patent target	Relative strength	Reason
Conventional 5 mg or 10 mg capsule	Low	Mature product with extensive prior art
Alternative filler system	Low	Often viewed as routine optimization
Fast-dissolving capsule	Low to moderate	Patent value depends on measurable performance
Orally disintegrating tablet	Moderate	Potential claims around excipient ratios and disintegration
Abuse-deterrent formulation	Moderate to high	Requires meaningful technical and clinical differentiation
Sublingual or buccal product	Moderate	Could alter onset and use profile
Pediatric liquid	Moderate	Requires stability, taste, dosing, and safety support
Sleep-maintenance extended release	Moderate to high	Different pharmacokinetic and clinical target
Manufacturing process	Moderate	Stronger if it solves impurity, content-uniformity, or scale-up problems

The strongest formulation patents would link composition to objective performance. Examples include a specified disintegration time, dissolution profile, impurity limit, capsule-fill uniformity, moisture stability, or pharmacokinetic result. Broad claims covering ordinary lactose, starch, cellulose, silica, and magnesium stearate combinations face significant obviousness risk.

What excipient strategies offer commercial opportunities?

Low-cost generic capsule platform

The lowest-risk opportunity is a conventional hard gelatin capsule using widely available excipients. A developer can pursue:

• 5 mg and 10 mg strengths.
• Common capsule-shell colors for product differentiation.
• Direct powder filling or validated dry blending.
• Multi-source excipient procurement.
• Packaging optimized for controlled-substance reconciliation.

The economic advantage comes from manufacturing reliability and low cost rather than intellectual property.

Orally disintegrating tablet

An orally disintegrating tablet could target patients who have difficulty swallowing capsules or who want administration without water. Suitable excipient categories include:

• Mannitol or other mouthfeel-improving diluents.
• Crospovidone or croscarmellose sodium as superdisintegrants.
• Low-substituted hydroxypropyl cellulose.
• Flavoring and sweetening systems.
• Direct-compression binders.
• Moisture-barrier blister packaging.

The principal technical risks are zaleplon taste, dose uniformity at low loading, friability, moisture sensitivity, and preservation of rapid absorption. The product would need to demonstrate that the dosage form does not materially change the clinical profile or produce unintended early peak concentrations.

Oral liquid or unit-dose solution

A liquid formulation could serve institutional, specialty, or administration-support markets. The formulation would require attention to:

• Zaleplon solubility.
• pH-dependent stability.
• Taste masking.
• Preservative compatibility.
• Sorbitol, glycerin, or other vehicle selection.
• Accurate dosing at 5 mg and 10 mg equivalents.
• Child-resistant packaging and controlled-substance controls.

A liquid product may have commercial value in hospitals, long-term-care facilities, and patients who cannot swallow capsules. Pediatric positioning would require separate clinical and regulatory support because FDA approval of adult insomnia treatment does not establish pediatric safety or efficacy.

Sprinkle or capsule-opening product

A capsule that can be opened and sprinkled onto a soft food could improve administration for selected patients. The design must preserve dose uniformity, stability, and rapid release after mixing. Regulatory labeling would need to define the permitted food vehicle, holding time, and administration method.

This option may offer a practical product improvement but usually produces weaker patent protection than a new delivery system.

Abuse-deterrent formulation

Zaleplon is a Schedule IV controlled substance. A formulation that reduces crushing, extraction, or rapid misuse could support a differentiated commercial position. Potential technologies include matrix systems, aversive agents, physical barriers, or tamper-evident packaging.

The regulatory and commercial burden is high. A sponsor would need abuse-deterrence testing, human abuse-potential data where applicable, and a clear clinical rationale. Packaging alone is easier to implement but less likely to support premium pricing or strong patent claims.

Sleep-maintenance formulation

SONATA’s short half-life is advantageous for sleep initiation but limits treatment of patients who wake during the night. An extended-release or biphasic formulation could target sleep initiation followed by sleep maintenance.

This is the most commercially differentiated formulation concept, but it changes the product’s risk profile. Longer exposure may increase next-day impairment, complex sleep behaviors, and interaction concerns. A new formulation would likely require a 505(b)(2) application with clinical bridging and potentially new safety studies rather than a simple ANDA.

What regulatory pathway applies to new zaleplon formulations?

Product concept	Likely FDA pathway
Equivalent 5 mg or 10 mg immediate-release capsule	ANDA
Same active ingredient with materially different dosage form	505(b)(2)
New release profile	505(b)(2)
New route of administration	505(b)(2), potentially with additional clinical evidence
New indication	505(b)(2) or full NDA depending on reliance and data
Conventional reformulation with no meaningful clinical change	Case-specific regulatory assessment

An ANDA must match the reference product’s dosage form, strength, route, active ingredient, and performance characteristics within the applicable FDA framework. A novel excipient, substantially higher excipient exposure, new route, or changed pharmacokinetic profile can move the product outside a routine ANDA strategy.

Which companies are challenging SONATA, and what is the litigation status?

Generic manufacturers have competed with SONATA through approved zaleplon capsule products. The original brand’s patent litigation cycle is historical rather than an active commercial issue. There is no broad current litigation barrier comparable to a still-protected blockbuster formulation.

The relevant competitive risks are:

1. Generic price erosion.
2. API supply concentration.
3. Controlled-substance distribution requirements.
4. Limited prescriber differentiation.
5. Reimbursement substitution.
6. Low switching friction among capsule products.

Settlement agreements relating to the original SONATA patent disputes would have historical relevance only unless a separate later formulation patent remains enforceable. No current settlement should be treated as a launch barrier without a live patent and enforceable restriction.

How does zaleplon compare with competing insomnia drugs?

Product	Primary advantage	Excipient and commercial implication
Zaleplon	Very short exposure; sleep-initiation use	Low-cost capsule platform; limited differentiation
Zolpidem	Large generic market and multiple dosage forms	Stronger competition, including tablets and extended-release products
Eszopiclone	Longer duration and sleep-maintenance positioning	Greater opportunity for differentiated release profiles
Ramelteon	Noncontrolled melatonin-receptor mechanism	Different safety and regulatory positioning
Suvorexant and related agents	Orexin pathway and sleep-maintenance claims	Higher branded value but more complex patent estates
Doxepin low dose	Sleep-maintenance positioning	Tablet formulation and generic competition

Zaleplon’s advantage is pharmacokinetic precision. Its weakness is the narrow commercial use case. A new product must preserve rapid onset while solving a specific administration, adherence, or sleep-maintenance problem.

What generic launch risks and revenue opportunities exist?

Revenue opportunity

The conventional generic capsule opportunity is volume-driven. Potential customers include retail pharmacies, mail-order pharmacies, hospital systems, long-term-care providers, and private-label distributors. Premium pricing is unlikely without a differentiated formulation, exclusive supply arrangement, or favorable distribution position.

A reformulated product could generate higher value through:

• Orally disintegrating administration.
• Unit-dose institutional packaging.
• A liquid for swallowing-impaired patients.
• A verified sprinkle option.
• Extended-release sleep-maintenance treatment.
• Abuse-deterrent positioning.

Launch risks

The main risks are commercial and regulatory rather than patent-based:

• A crowded generic supplier field.
• Rapid price compression after additional ANDA approvals.
• Controlled-substance quota and distribution requirements.
• API impurity or stability issues.
• Low prescription growth in a mature insomnia category.
• Limited willingness of payers to reimburse a premium.
• Clinical concern over next-day impairment if exposure is prolonged.

A new entrant should expect the conventional capsule market to reward manufacturing efficiency, supply reliability, and channel access. An improved dosage form offers more defensible economics but requires greater development expenditure and clinical evidence.

What geographic markets offer the best opportunity?

The United States offers a straightforward generic pathway but has strong price competition. European and other regulated markets may offer opportunities for differentiated administration, but product names, controlled-substance rules, reference products, and patent assessments vary by jurisdiction.

Region	Opportunity
United States	ANDA generic capsules; 505(b)(2) differentiated formulations
European Union	National or decentralized generic filings; formulation differentiation
Japan	Local regulatory and clinical requirements; potentially lower-volume specialty market
Emerging markets	Lower-cost capsules and institutional supply
Long-term-care channels	Liquid, unit-dose, and administration-friendly formats

Patent protection must be assessed country by country. Expiry of U.S. rights does not establish freedom to operate in Europe, Japan, China, or other markets.

Key Takeaways

• SONATA is zaleplon, an FDA-approved short-acting insomnia drug available mainly through generic capsules.
• The original patent and exclusivity barriers have expired.
• The conventional excipient system uses common diluents, binders, glidants, lubricants, surfactants, and gelatin capsule materials.
• Generic capsule entry is a low-risk regulatory opportunity but a low-margin commercial opportunity.
• The strongest formulation opportunities are orally disintegrating tablets, liquid or sprinkle products, abuse-deterrent systems, and sleep-maintenance formulations.
• New excipient patents need measurable technical effects, not routine substitution of lactose, cellulose, starch, silica, or magnesium stearate.
• An ANDA is appropriate for an equivalent immediate-release capsule. A novel dosage form or release profile is more likely to require a 505(b)(2) application.
• There is no biosimilar pathway because zaleplon is a small molecule.
• The principal current risks are generic price erosion, controlled-substance distribution, API supply, and limited patient willingness to pay for reformulation.

FAQs About SONATA Excipient and Commercial Strategy

Can zaleplon be developed as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could address swallowing difficulty and administration without water, but taste masking, rapid disintegration, low-dose uniformity, moisture stability, and bioequivalence would require specific development work.

Would a new zaleplon excipient combination receive patent protection?

Only if the combination produces a defensible and unexpected technical result. Routine substitution among common fillers, binders, disintegrants, and lubricants is unlikely to support broad, durable claims.

Is a zaleplon liquid formulation commercially attractive?

It can be attractive in institutional, long-term-care, and swallowing-impaired populations. The opportunity is constrained by taste, stability, controlled-substance packaging, dosing accuracy, and the need to establish a commercially viable channel.

Can a generic company file Paragraph IV against SONATA today?

A Paragraph IV filing is relevant only to an unexpired Orange Book-listed patent. The original SONATA patent barriers are historical and do not generally prevent ordinary generic zaleplon capsule entry.

Could extended-release zaleplon compete with zolpidem and eszopiclone?

Yes, but it would target a different clinical profile focused on sleep maintenance. The formulation would face higher development, safety, and regulatory requirements because prolonged exposure could increase next-day impairment and alter the established zaleplon risk-benefit profile.

References

1. U.S. Food and Drug Administration. (1999). SONATA (zaleplon) prescribing information. FDA Drugs@FDA.
2. National Library of Medicine. (n.d.). DailyMed: Zaleplon capsule. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database, NDA 020859. FDA.